Toxic Epidermal Necrolysis After Celecoxib Therapy

Berger, Peter B.; Dwyer, Daniel; Corallo, Carmela

doi:10.1592/phco.22.13.1193.33513

Cited by 21 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, the only previous case of a positive patch test reaction to celecoxib was described in a patient who developed an exanthema following the use of this drug (3). Celecoxib has also been associated with allergic vasculitis (4, 5), fixed drug eruption (6), toxic epidermal necrolysis (7–9), erythema multiforme (10), Sweet's syndrome (11) and anaphylaxis (12–14).…”

Section: Commentmentioning

confidence: 99%

Cutaneous reaction to oral celecoxib with positive patch test

2004

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

Cutaneous reaction to oral celecoxib with positive patch test

2004

View full text Add to dashboard Cite

“…In addition, the pattern of skin involvement in rheumatoid arthritis may be changing to shadow the evolution of treatment practices-for example, the early use of disease-modifying anti-rheumatic drugs (DMARDs), alone or in combination, [12][13][14][15][16] and the introduction of new treatments such as the biologicals 9 or some cyclooxygenase-2 inhibitors. [17][18][19] In the present study, we aimed to determine the prevalence and characteristics of dermatological disorders in contemporary patients with rheumatoid arthritis and compare this with a group of patients with non-inflammatory rheumatic conditions.…”

mentioning

confidence: 99%

Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions

Douglas

Ladoyanni²,

Treharne³

et al. 2006

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Background: Cutaneous abnormalities are common in rheumatoid arthritis, but exact prevalence estimates are yet to be established. Some abnormalities may be independent and coincidental, whereas others may relate to rheumatoid arthritis or its treatment. Objectives: To determine the exact nature and point prevalence of cutaneous abnormalities in patients with rheumatoid arthritis compared with those in patients with non-inflammatory rheumatic disease. Methods: 349 consecutive outpatients for rheumatology (205 with rheumatoid arthritis and 144 with noninflammatory rheumatic conditions) were examined for skin and nail signs by a dermatologist. Histories of rheumatology, dermatology, drugs and allergy were noted in detail. Results: Skin abnormalities were reported by more patients with rheumatoid arthritis (61%) than noninflammatory controls (47%). More patients with rheumatoid arthritis (39%) than controls (10%) attributed their skin abnormality to drugs. Cutaneous abnormalities observed by the dermatologist were also more common in patients with rheumatoid arthritis (76%) than in the group with non-inflammatory disease (60%). Specifically, bruising, athlete's foot, scars, rheumatoid nodules and vasculitic lesions were more common in patients with rheumatoid arthritis than in controls. The presence of bruising was predicted only by current steroid use. The presence of any other specific cutaneous abnormalities was not predicted by any of the variables assessed. In the whole group, current steroid use and having rheumatoid arthritis were the only important predictors of having any cutaneous abnormality. Conclusions: Self-reported and observed cutaneous abnormalities are more common in patients with rheumatoid arthritis than in controls with non-inflammatory disease. These include cutaneous abnormalities related to side effects of drugs or to rheumatoid arthritis itself and other abnormalities previously believed to be independent but which may be of clinical importance.

show abstract

“…Structurally, celecoxib is a benzenesulfonamide derivative containing a sulfonamide moiety 4,5 . This perhaps explains the numerous cutaneous side‐effects recorded with celecoxib, including maculopapular eruption, 6 cutaneous vasculitis, 2 fatal allergic vasculitis, 1 toxic epidermal necrolysis, 7 urticaria and angioedema, 8 Sweet's syndrome, 9 anaphylaxis, 4 photosensitivity with pseudoporphyria, 10 and erythema multiforme 5 …”

Section: Discussionmentioning

confidence: 99%

Celecoxib‐induced photoallergic drug eruption

Yazıcı¹,

Baz²,

İkizoğlu³

et al. 2004

Int J Dermatology

View full text Add to dashboard Cite

Photoallergic dermatitis is caused by a photosensitizing substance plus sunlight exposure in a sensitized person. If the photosensitizer is delivered internally, it is called a photoallergic drug reaction. Celecoxib is a new generation non-steroidal anti-inflammatory drug and sulfonamide derivative. We report a photoallergic drug eruption associated with the introduction of celecoxib. To our knowledge, this is the first report of photoallergic drug reaction associated with celecoxib.

show abstract

Toxic Epidermal Necrolysis After Celecoxib Therapy

Cited by 21 publications

References 9 publications

Cutaneous reaction to oral celecoxib with positive patch test

Cutaneous reaction to oral celecoxib with positive patch test

Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions

Celecoxib‐induced photoallergic drug eruption

Contact Info

Product

Resources

About